Últimos Artículos de Lancet Diabetes & Endocrinology
- [Correspondence] Policies on ultra-processed diets: feasible and urgent
- [Editorial] Reassessing driving safety in diabetes
- [Articles] Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
- [Comment] Body composition during major incretin-based weight loss
- [Comment] Maternal thyroid hypofunction and gestational diabetes risk
- [Articles] Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis
- [Clinical Picture] From prominent corneal nerves to multiple endocrine neoplasia type 2B
- [Corrections] Correction to Lancet Diabetes Endocrinol 2025; 13: 580–90
- [Comment] Type 2 diabetes, prediabetes, and MASLD: who and when to screen and how to treat?
- [Articles] Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial
- [Comment] More options for young children with type 1 diabetes
- [Personal View] Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
- [Correspondence] Prevalence of clinical obesity versus BMI-defined obesity among US adults: a cohort study
- [Articles] Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis
- [Comment] Experience evolves into evidence in the new MEN1 guidelines
- [Review] Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice
- [Comment] Underrepresentation of older adults in diabetes and kidney disease trials
- [Editorial] Childhood obesity: prioritising a healthy start
- [Articles] Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
- [Articles] Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial